With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of ...

Early toxicities associated with a 3-week hypofractionated radiotherapy regimen do not raise initial safety concerns in women ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients lived without the disease worsening, but failed to achieve statistically ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor ...